Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety

Case ID:

This invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action.


Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics are associated with a number of side effects including an increased risk of suicidal thoughts in those taking antidepressants. Therefore, a novel pathway is needed for rapid onset with minimal side effects.



  • Pharmaceutical companies



  • Provides a treatment for depressive and anxiety disorders

Status: issued U.S. patent #11,542,302

Patent Information:
Contact For More Information:
Jonathan Larson
Senior Licensing Manager, College of Science
The University of Arizona
Lead Inventor(s):
Victor Hruby
Minying Cai